Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center
Abstract
Aims: In the USA, transthyretin cardiac amyloidosis usually results from ‘wild-type’ transthyretin (senile cardiac amyloidosis [SCA]) or the V122I variant. Patients & methods: We compared presentations and outcomes among SCA and V122I patients referred to the Center for Advanced Cardiac Care at Columbia University Medical Center (NY, USA) between 2001 and 2012. Results: V122I patients were younger (mean: 71 years, standard deviation [SD]: 7) than SCA patients (mean: 77, SD: 6; p = 0.0002) and 96% were black compared with 3% of SCA patients (p < 0.0001). Average ejection fraction was lower among V122I patients (mean: 25% [SD: 12] vs mean: 47% [SD: 15]; p = 0.0001), as was mean cardiac index. Median time to death or orthotopic heart transplant was 36.4 months for V122I patients and 66.5 for SCA patients (p = 0.09). Conclusion: In this study of patients with transthyretin cardiac amyloidosis, V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability. There was a trend toward shorter time to orthotopic heart transplant or death among V122I patients. Whether this is a result of a different biologic progression or late diagnosis requires further study.
References
- 1 Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J. Am. Geriatr. Soc.60,765–774 (2012).Crossref, Medline, Google Scholar
- 2 Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation126,1286–1300 (2012).Crossref, Medline, Google Scholar
- 3 Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry35,6470–6482 (1996).Crossref, Medline, CAS, Google Scholar
- 4 Jacobson DR, Pastore R, Pool S et al. Revised transthyretin Ile 122 allele frequency in African–Americans. Hum. Genet.98,236–238 (1996).Crossref, Medline, CAS, Google Scholar
- 5 Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African–American population. Amyloid12,127–130 (2005).Crossref, Medline, CAS, Google Scholar
- 6 Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA98,14943–14948 (2001).Crossref, Medline, CAS, Google Scholar
- 7 Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod. Pathol.2,372–377 (1989).Medline, CAS, Google Scholar
- 8 Dungu J, Sattianayagam PT, Whelan CJ et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro–Caribbean patients. Am. Heart J.164,72–79 (2012).Crossref, Medline, CAS, Google Scholar
- 9 Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African–American men. Am. J. Cardiol.108,440–444 (2011).Crossref, Medline, CAS, Google Scholar
- 10 Connors LH, Prokaeva T, Lim A et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am. Heart J.158,607–614 (2009).Crossref, Medline, CAS, Google Scholar
- 11 Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am. Heart J.159,864–870 (2010).Crossref, Medline, CAS, Google Scholar
- 12 Ruberg FL, Maurer MS, Judge DP et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am. Heart J.164,222–228.e1 (2012).Crossref, Medline, CAS, Google Scholar
- 13 Bulawa CE, Connelly S, Devit M et al. Tafamid is, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA109,9629–9634 (2012).Crossref, Medline, CAS, Google Scholar
- 14 de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today48,331–337 (2012).Crossref, Medline, CAS, Google Scholar
- 15 Castano A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest. Heart Fail.18(6),315–319 (2012).Crossref, Medline, CAS, Google Scholar
- 16 Ackermann EJ, Guo S, Booten S et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid19(Suppl. 1),43–44 (2012).Crossref, Medline, CAS, Google Scholar
- 0101 Ensembl genome browser. www.ensembl.org (Accessed 15 January 2013)Google Scholar
- 102 Rastogi SJ, Johnson TD, Hoeffel EM, Drewery MP. The black population: 2010. US Census Bureau. www.census.gov/prod/cen2010/briefs/c2010br-06.pdf (Accessed 15 January 2013)Google Scholar
- 103 Alnylam Pharamceuticals. www.alnylam.com (Accessed 21 January 2013)Google Scholar
